Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its subsidiary Sapu Nano will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego. The presentation focuses on tissue concentration–driven effects and organ-specific outcomes beyond traditional plasma pharmacokinetics, highlighting the importance of tissue-level drug distribution in determining toxicity profiles. This research supports the development of improved delivery strategies, including intravenous and nanoparticle-based formulations.
The findings are expected to advance the understanding of how everolimus, a mTOR inhibitor used in various cancers, can be optimized to reduce side effects while maintaining efficacy. By examining drug accumulation in specific tissues, Sapu Nano aims to identify safer dosing regimens and inform the design of next-generation nanomedicines. The presentation underscores a shift from conventional plasma-based monitoring to a more nuanced approach that considers local drug concentrations.
Oncotelic, through its wholly owned subsidiary Sapu Nano, is committed to leveraging nanotechnology to enhance therapeutic index and unlock new clinical potential. The company’s pipeline includes treatments for rare pediatric cancers, melanoma, and acute myeloid leukemia, as well as intranasal apomorphine for Parkinson’s disease. The everolimus toxicology data aligns with Oncotelic’s broader strategy of improving drug delivery via its nanomedicine platform. For more details on the press release, visit https://ibn.fm/kZzE3.
Oncotelic also continues to advance its AI-driven drug development capabilities through its acquisition of PointR Data Inc. and is developing AL-101 for neurological and sexual health disorders. The company’s focus on rare pediatric cancers remains a priority, with rare pediatric designations for diffuse intrinsic pontine glioma (DIPG), melanoma, and acute myeloid leukemia. The everolimus data presentation at SOT 2026 represents a key milestone in Sapu Nano’s efforts to translate tissue-level toxicology insights into safer, more effective cancer therapies.
Investors can find the latest news and updates on OTLC at the company’s newsroom: https://ibn.fm/OTLC. The SOT 2026 annual meeting will provide a platform for Sapu Nano to share its findings with the toxicology community, potentially influencing future drug development paradigms.
